Back to top
more

Xenetic Biosciences (XBIO)

(Delayed Data from NSDQ)

$4.09 USD

4.09
667

+0.31 (8.32%)

Updated Apr 26, 2024 02:49 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XBIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Xenetic Biosciences, Inc. [XBIO]

Reports for Purchase

Showing records 1 - 20 ( 21 total )

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 1

03/22/2024

Company Report

Pages: 6

2023 Results; 2024 Brings Prospects of Phase 1 Pancreatic Carcinoma Study; Financial Strains Persist

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 2

11/10/2023

Company Report

Pages: 6

3Q23 Results; Phase 1 Pancreatic Carcinoma Study Slated For 2024; Significant Financial Overhang Remains

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 3

05/16/2023

Company Report

Pages: 6

Waiting For Line of Sight to Clinic; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 4

04/11/2023

Daily Note

Pages: 5

New Collaboration Supports Advancement of DNase-Based Platform Toward the Clinic

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 5

03/23/2023

Company Report

Pages: 7

2022 Results; DNase-Based Platform Aims to Differentiate With Approaching Phase 1 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 6

11/10/2022

Company Report

Pages: 7

3Q22 Results; DNAse-Based Oncology Platform Getting Ready to Initiate Clinical Journey

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 7

08/12/2022

Company Report

Pages: 7

2Q22 Results; With Recent Shift In Focus to DNAse-Based Oncology Platform, All Eyes on Starting Phase 1 Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 8

05/13/2022

Company Report

Pages: 7

1Q22 Results; DNAse-Based Oncology Platform Marches Towards Clinical Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 9

05/02/2022

Company Report

Pages: 7

Focus Builds with Pipeline Addition; Price Target Adjusted to $4

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 10

04/28/2022

Company Report

Pages: 7

Intriguing Addition to Pipeline; NETs Being Targeted in Oncology; Doors Can Open to Further Immune Killing of Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 11

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for XBIO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 12

08/13/2021

Company Report

Pages: 6

2Q21 Results; Progress Continues Toward IND-Enabling Studies for XCART

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 13

05/12/2021

Company Report

Pages: 6

1Q21 Results; Continuing to Build the XCART Profile

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 14

03/17/2021

Company Report

Pages: 6

2020 Results; Key Focus on Moving XCART to the Clinic

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 15

02/16/2021

Daily Note

Pages: 4

Positive Partner Headline Using PolyXen; Focus on XCART Initial Clinical Steps in 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 16

01/11/2021

Company Report

Pages: 6

Expecting Meaningful Visibility Boost from XCART Program in 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 17

11/13/2020

Company Report

Pages: 8

3Q20 Results; Progress Continues Towards XCART Clinical Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 18

08/13/2020

Company Report

Pages: 8

2Q20 Results; Key Collaborations Are Set to Push XCART Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 19

06/17/2020

Company Report

Pages: 8

Xenetic Delivers Key Collaboration to Move XCART Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Xenetic Biosciences, Inc.

Industry: Medical - Drugs

Record: 20

05/19/2020

Daily Note

Pages: 5

Cozying up to Scripps to Push XCART Closer to the Clinic

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party